Tarsons Q1 FY27: Revenue growth stays strong, but margins and PAT remain under pressure

Tarsons Products Limited reported a strong start to FY27 on the top line, with consolidated revenue rising 21% year on year to INR 110.2 crores for the quarter ended June 30, 2026. Standalone revenue also increased 21% to INR 86.1 crores. The company attributed the performance to improving demand conditions, deeper customer engagement, and a rebound in exports.

But the quarter also highlighted a familiar gap between revenue momentum and reported profitability. Consolidated EBITDA grew 5% year on year to INR 26.0 crores, while EBITDA margin fell to 23.6% from 27.0%. Consolidated PAT turned negative at INR 1.4 crores, compared with a profit of INR 1.8 crores in Q1 FY26. On the standalone books, PAT fell sharply to INR 0.7 crores from INR 3.6 crores.

Management’s message was clear: raw material inflation and the cost base of newly commissioned facilities are weighing on margins today, while the full revenue potential from new capacities is expected to show up more meaningfully from FY28 onwards.

What drove the 21% growth

The company’s Q1 FY27 consolidated revenue was supported by growth across key engines.

Standalone domestic revenue increased from INR 48.1 crores in Q1 FY26 to INR 56.3 crores in Q1 FY27, a 17% year-on-year increase. Management linked this to a revival in demand across product categories and the strength of its distribution network.

Standalone export revenue increased from INR 23.2 crores to INR 29.9 crores, up 29% year on year. On the call, management said the previous quarters were disrupted by geopolitical tensions in West Asia and uncertainty around tariffs, and that export order pipelines and inquiry levels have now recovered with healthier conversions.

The Nerbe subsidiary reported revenue of INR 24.1 crores in Q1 FY27 versus INR 20.1 crores in Q1 FY26, up 20% year on year in the investor presentation. On the call, management noted that Nerbe delivered about 6% year-on-year growth in constant currency terms and continues to show resilience despite a challenging operating environment.

The company stressed that the quarter’s growth came largely from the existing product portfolio, with limited contribution from newer product categories and new capacities. Management positioned this as evidence of underlying franchise strength, while also pointing to additional headroom as new lines ramp up.

Margin compression: polymer inflation and new facility costs

Margins were the key pressure point in the quarter.

Standalone gross margin declined to 67.1% from 71.4%, and consolidated gross margin declined to 64.9% from 67.9%. Management attributed this to higher raw material prices driven by supply chain disruptions and geopolitical challenges. On the call, management said key input costs increased in the range of 25% to 50%.

Standalone EBITDA rose to INR 24.2 crores from INR 22.2 crores, but EBITDA margin declined to 28.1% from 31.2%. Consolidated EBITDA rose to INR 26.0 crores from INR 24.7 crores, while EBITDA margin fell to 23.6% from 27.0%.

In addition to input costs, management cited commissioning and operating expenses related to the new Amta and Panchla facilities, which have partially commenced commercial operations.

The company said it implemented partial price increases during the quarter to mitigate inflation, with the full benefit expected to flow through with a one-quarter lag. However, management also acknowledged limited ability to take price hikes in international markets, saying price increases abroad were close to zero due to competitive dynamics and inventory overhang in the system.

Financial snapshot

PAT impact: depreciation, finance cost, and consolidation items

A sharp rise in depreciation and finance costs materially impacted reported profits.

Standalone depreciation rose to INR 24.6 crores from INR 17.8 crores. Standalone finance cost increased to INR 5.4 crores from INR 4.3 crores. Consolidated depreciation rose to INR 27.0 crores from INR 19.9 crores and consolidated finance cost increased to INR 6.3 crores from INR 5.1 crores.

Management discussed that higher depreciation and interest costs are associated with the new capex at Amta and Panchla. The investor presentation stated that these new facilities are expected to contribute meaningfully from FY28 and FY29.

The company also provided a bridge between standalone and consolidated PAT for Q1 FY27. Standalone PAT of INR 0.7 crores was reduced by consolidation eliminations and subsidiary items, resulting in consolidated PAT of negative INR 1.4 crores. The bridge included elimination of SBLC commission booked in Tarsons books, interest paid to bank by the subsidiary, and elimination of amortisation on intangible assets acquired, offset partly by Nerbe PAT.

Despite weak accounting PAT, management repeatedly pointed to cash profitability. Cash PAT increased 18% year on year to INR 25.6 crores on a consolidated basis and to INR 25.2 crores on a standalone basis.

Capacity ramp-up and new product categories: what is changing

Tarsons has been executing a multi-year capacity expansion program aimed at strengthening manufacturing capabilities and expanding the product portfolio. Management said the company is in the final phase of this expansion journey, with a substantial part of planned capex already commissioned and operational.

Two facilities are central to the ramp-up narrative.

Amta, West Bengal: The investor presentation stated that Amta includes a new fulfillment center with in-house sterilization as well as manufacturing capability, and that revenue from the new capacity commenced from Q4 FY26.

Panchla, West Bengal: The company is expanding into new product categories and capacity at Panchla, including entry into the cell culture segment. The investor presentation expects revenue from new categories of cell culture to begin from H2 FY27.

On the call, management acknowledged that commercial commissioning at Panchla has been delayed compared to earlier expectations, citing the scale and number of projects, and reliance on external engineering teams. Management guided that cell culture lines at Panchla are expected to be commissioned towards the end of Q2 FY27.

Management also said that while cell culture consumables did not contribute in Q1 FY27, Panchla contributed revenue from existing products or capacity expansions relocated into Panchla. It also mentioned contribution from bioprocess containers such as media bottles and roller bottles.

Exports, white labeling, and Nerbe integration

Export expansion remains a strategic theme. The investor presentation noted that as of March 31, 2026, Tarsons sold products to 40+ countries via 45+ distributors, and that export operations are a blend of branded and ODM sales. The export mix was presented as 66% branded and 34% ODM in FY26.

On the call, management said it is seeing encouraging opportunities in white labeling and expects it to be a key growth driver in exports. It also highlighted that international trade fairs and exhibitions are contributing to inquiries and customer additions.

Nerbe is expected to play a role in international scaling. Management described Nerbe as having a strong network and customer relationships in Germany and the EU, and highlighted an opportunity to cross-sell Tarsons-manufactured products through Nerbe’s network.

Balance sheet: debt and capex intensity

Leverage remains elevated due to the capex cycle. On the call, the CFO stated gross debt of about INR 380 crores and net debt of about INR 330 to 340 crores.

The CFO indicated loan repayments of around INR 70 crores and said net debt could reduce by about INR 40 crores year on year in FY27. The CFO also stated there is no major capex planned, apart from maintenance and required capex.

On depreciation, the CFO noted that depreciation in Q1 FY27 included contributions from Panchla and Amta, and that there is around INR 160 crores of capital work in progress expected to be capitalised in subsequent quarters. Full-year depreciation guidance was indicated at approximately INR 105 crores.

Takeaways

Tarsons delivered a strong revenue quarter in Q1 FY27, with domestic recovery and export rebound driving 21% year-on-year growth in consolidated revenue. The company’s core portfolio appears to be gaining traction again, and management believes customer inquiry levels support sustained demand momentum.

However, the quarter also made clear that the capex cycle is still in the earnings absorption phase. Polymer inflation, commissioning costs, higher depreciation, and higher interest expenses are constraining reported profitability. Management expects the financial benefits of the capacity expansion and new product launches to become increasingly visible from FY28 onwards, as utilization improves and operating leverage kicks in.

The near-term monitoring points remain commissioning progress at Panchla, the pace of ramp-up in new product categories including cell culture, and whether pricing actions can offset raw material volatility without sacrificing competitive position.